News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zafgen (ZFGN) Reports Second Quarter 2017 Financial Results



8/9/2017 1:34:23 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
BOSTON, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), today announced its second quarter 2017 financial results.

“In the second quarter, we reached a critical milestone in the development program for ZGN-1061, demonstrating its favorable safety and pharmacokinetic profile with the results of the Phase 1 clinical trial of our optimized MetAP2 inhibitor, as well as early efficacy signals for ZGN-1061’s potential to improve glycemic control and body weight,” said Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen.

Read at GlobeNewswire


comments powered by Disqus
Zafgen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES